HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Most conversations about women's hormones focus on what the body makes. Far fewer examine what the body does with hormones after they circulate — and specifically whether the enzymatic infrastructure that clears them is running at full capacity. That infrastructure is built on methylation, and the genetic variable that governs methylation throughput is MTHFR — methylenetetrahydrofolate reductase. MTHFR variants don't affect how much estrogen your body produces. They affect how efficiently the downstream clearing machinery can do its job. For women navigating hormonal cycles, perimenopause, or estrogen-pathway support of any kind, MTHFR is the upstream genetic variable that determines whether Phase 2 estrogen clearance has the fuel it needs. The PlexusDx Precision Peptide Genetic Test analyzes MTHFR C677T and A1298C as part of 14 pathways, 49 peptides, and 150+ genetic insights — placing methylation capacity within the full Reproductive Health pathway context.

The Methylation Cycle: How MTHFR Feeds Estrogen Clearance

The methylation cycle is a continuous biochemical process that transfers methyl groups (–CH₃) to hundreds of cellular substrates — DNA, proteins, neurotransmitters, and hormones among them. The cycle's central output is SAMe (S-adenosylmethionine), the universal methyl donor that powers methylation reactions throughout the body. MTHFR sits at the rate-limiting step of that cycle.

The pathway flows as follows: dietary folate is reduced to dihydrofolate (DHF), then tetrahydrofolate (THF), then 5,10-methylenetetrahydrofolate. MTHFR converts that intermediate to 5-methyltetrahydrofolate (5-MTHF) — the bioactive, circulating form of folate. 5-MTHF donates its methyl group to homocysteine (via the enzyme MTR, dependent on vitamin B12), converting it back to methionine. Methionine is then activated to SAMe, which donates methyl groups across the body's methylation network.

The critical downstream destination of that SAMe, for estrogen biology, is COMT — catechol-O-methyltransferase. COMT methylates the catechol estrogens (2-OHE2 and 4-OHE2) produced by Phase 1 hydroxylation via CYP1A1 and CYP1B1, inactivating them for excretion. COMT is methylation-dependent — without adequate SAMe, it operates below its functional capacity regardless of COMT genotype. An MTHFR variant that reduces 5-MTHF production therefore constrains SAMe availability, which constrains COMT activity, which slows estrogen clearance. The full Phase 1 context is covered in CYP1A1 and CYP1B1: Estrogen Metabolism Pathways; the COMT clearance step in detail is covered in COMT Val158Met and Estrogen Clearance.

MTHFR C677T: The Primary Functional Variant

C677T (rs1801133) is a missense variant in exon 4 of the MTHFR gene — a single nucleotide change that substitutes alanine for valine at amino acid position 222 of the enzyme. The resulting protein is thermolabile: at physiological temperatures, the C677T variant enzyme loses its cofactor riboflavin (FAD) more readily than the wild-type, reducing enzymatic stability and catalytic efficiency.

The functional consequences are dose-dependent and well-established across extensive population research:

C677T heterozygous (C/T): One copy of the variant allele. Enzyme activity is approximately 35% lower than wild-type (C/C) in erythrocyte assays and comparable tissue samples across multiple published studies. 5-MTHF production is meaningfully reduced; SAMe availability is partially constrained.

C677T homozygous (T/T): Both copies carry the variant. Enzyme activity is approximately 60–70% lower than wild-type — the most functionally significant single-variant MTHFR genotype. Plasma homocysteine is elevated (reflecting reduced remethylation capacity), and the folate-to-5-MTHF conversion bottleneck is substantial. Women with T/T genotype have the most significantly impaired methylation throughput of any MTHFR single-variant group.

C677T is more common in certain populations — carrier frequencies vary widely by ancestry, with homozygous T/T rates ranging from approximately 8–15% in European-ancestry populations to higher rates in some Latin American and Mediterranean populations. This is a common variant, not a rare mutation — a meaningful fraction of women carry it without knowing.

MTHFR A1298C: The Secondary Functional Variant

A1298C (rs1801131) is located in exon 7 of MTHFR, in the regulatory domain of the enzyme rather than the active site. The functional mechanism differs from C677T: A1298C affects enzyme allosteric regulation rather than thermostability. The C allele (variant) is associated with approximately 40% reduced enzyme activity in heterozygous carriers.

A1298C homozygous (C/C) is less common than C677T homozygous and tends to produce a less severe isolated methylation impairment than T/T C677T. However:

Compound heterozygous (C677T/A1298C): Carrying one copy of each variant — one C677T allele and one A1298C allele on the same or different chromosomes — is an important and commonly overlooked genotype combination. The two variants additively impair methylation capacity: studies consistently show that compound heterozygotes have intermediate-to-severe methylation impairment, with elevated homocysteine and reduced 5-MTHF production that approximates T/T C677T in some measurement contexts. The Precision Peptide Genetic Test identifies both variants — and therefore captures compound heterozygous status — which single-variant testing misses entirely.

The MTHFR-Estrogen Clearance Chain Specific to Women

The mechanistic link between MTHFR impairment and women's hormonal health runs through a specific chain — one that becomes most clinically relevant when estrogen levels are elevated, fluctuating, or being supplemented:

Step 1: MTHFR impairment reduces 5-MTHF production, constraining the methyl group supply entering the methylation cycle.

Step 2: Less 5-MTHF means less homocysteine remethylation to methionine, which means less methionine available for SAMe synthesis. Plasma homocysteine rises as a measurable downstream signal of this impairment.

Step 3: Reduced SAMe availability limits COMT enzymatic throughput. COMT relies on SAMe as its methyl donor for every methylation reaction — including the methylation of 2-OHE2 and 4-OHE2 after Phase 1 hydroxylation. Lower SAMe means COMT runs slower regardless of COMT genotype.

Step 4: Slower COMT-mediated estrogen clearance extends the dwell time of catechol estrogens in circulation and tissue — sustaining their biological activity and, in the case of 4-OHE2, their potential for reactive quinone formation if glutathione conjugation by GSTM1/GSTT1 is also insufficient.

The compound scenario — impaired MTHFR feeding impaired COMT feeding elevated catechol estrogens — creates a functional estrogen clearance bottleneck that operates even when estradiol production itself is normal. Understanding this upstream-to-downstream chain is why the Precision Peptide Genetic Test analyzes MTHFR alongside COMT, CYP1A1/CYP1B1, and GSTM1/GSTT1 as a connected system rather than isolated variants.

MTHFR, the Hormonal Cycle, and Perimenopause

The MTHFR-estrogen clearance connection has distinct relevance at several hormonal life stages:

Active hormonal cycles: During the luteal phase, estradiol peaks and then falls — a process that depends on efficient Phase 1 and Phase 2 metabolism for timely clearance before the next cycle. Impaired methylation (from MTHFR variants reducing SAMe → COMT activity) can prolong estrogen activity in the luteal phase, potentially contributing to the hormonal symptom burden some women experience premenstrually. This is a tendency, not a diagnosis — but it is a genetically explicable mechanism behind a symptom pattern that bloodwork alone often cannot characterize.

Perimenopause transition: During perimenopause, estradiol levels fluctuate more widely than at any other life stage — cycling unpredictably between high and low as ovarian function becomes irregular. Each estradiol peak represents a clearing event: Phase 1 must hydroxylate the surge; Phase 2 must methylate and conjugate the resulting catechol estrogens. A woman with MTHFR-impaired SAMe production faces each perimenopausal estradiol surge with less methylation reserve than an MTHFR wild-type woman — potentially contributing to the intensity and variability of perimenopausal hormonal symptoms.

Estrogen-pathway support protocols: Any protocol that adds exogenous estrogen to circulation increases the total hydroxylation and clearance burden. The same MTHFR-mediated SAMe constraint that slows clearance of endogenous catechol estrogens applies to catechol estrogens derived from exogenous sources. For women considering estrogen-pathway support, MTHFR genotype is a foundational variable a provider needs before beginning — informing whether methylation support should be established first, and which folate forms will actually support MTHFR-impaired pathways.

MTHFR, Folate, and Reproductive Health Beyond Hormones

In women of reproductive age, MTHFR's role extends beyond estrogen clearance into the folate-dependent biological processes that directly affect fertility and early pregnancy:

Neural tube development: Adequate folate status is essential in the peri-conception period for neural tube closure in early fetal development. MTHFR T/T homozygotes convert dietary folic acid to 5-MTHF less efficiently — meaning standard folic acid supplementation at the recommended dose may not achieve the same circulating 5-MTHF levels as in wild-type women. This is why MTHFR genotype is clinically relevant to prenatal supplementation strategy: women with T/T genotype or compound heterozygous status are typically better supported by direct 5-MTHF supplementation rather than folic acid, which requires the impaired MTHFR enzyme to activate it.

Homocysteine and implantation: Elevated homocysteine — a direct consequence of MTHFR-impaired remethylation — has been associated in the research literature with endothelial function and implantation biology. Normalizing homocysteine through targeted B-vitamin support (5-MTHF, methylcobalamin, B6) is an important consideration in the reproductive health context for women with MTHFR impairment. The Precision Peptide Genetic Test identifies MTHFR variants so this dimension is visible before fertility goals are actively pursued.

Mood and cognitive function in the hormonal context: MTHFR also governs the methylation of neurotransmitter systems — including serotonin and dopamine metabolism pathways. In women, the interaction between hormonal fluctuations and methylation-dependent neurotransmitter processing can contribute to cycle-related mood variability. MTHFR genetics are part of this picture, connecting the Reproductive Health pathway to the Mood pathway in the broader 14-pathway panel structure.

The Folate Form Question: Why Folic Acid Is Not Always the Answer

Standard folic acid — the synthetic form found in most multivitamins and fortified foods — requires MTHFR to convert it to the bioactive 5-MTHF that enters the methylation cycle. For women with C677T T/T or compound heterozygous genotype, this conversion is substantially impaired. Supplementing with folic acid at standard doses may not meaningfully raise circulating 5-MTHF levels if the MTHFR enzyme cannot efficiently perform the conversion.

The clinical implication is direct: MTHFR genotype determines which folate form a provider recommends. Wild-type women convert folic acid normally — standard supplements work. T/T or compound heterozygous women need the pre-activated form — 5-MTHF (also called L-methylfolate or (6S)-5-methyltetrahydrofolic acid) — to bypass the impaired MTHFR conversion step and directly feed the methylation cycle. The Precision Peptide Genetic Test identifies which genotype a woman carries, providing the information a provider needs to recommend the appropriate folate form before any prenatal, hormonal, or methylation support strategy begins.

MTHFR in the Full Women's Hormone Genetic Panel

MTHFR sits at the upstream methylation layer of the Women's Hormone pathway — the enzymatic source of SAMe that the rest of the estrogen clearance cascade depends on. Its connections to the full panel — covered in the Complete Guide to Genetic Women's Hormone Testing:

COMT — the primary downstream SAMe consumer in estrogen clearance. COMT uses SAMe to methylate catechol estrogens. MTHFR impairment starves COMT of its methyl donor substrate — slowing clearance even when the COMT Val158Met genotype is wild-type. The MTHFR-COMT interaction is the most direct genetic mechanism connecting methylation to estrogen accumulation. COMT Val158Met and Estrogen Clearance covers the Phase 2 methylation step in full.

CYP1A1 / CYP1B1 — Phase 1 producers of COMT's catechol estrogen substrates. The catechol estrogens that COMT must methylate are produced by CYP1A1 and CYP1B1. High-activity CYP1B1 variants increase 4-OHE2 production — placing greater demand on COMT's methyl donor supply at exactly the point where MTHFR impairment limits that supply. CYP1A1 and CYP1B1: Estrogen Metabolism Pathways covers Phase 1 hydroxylation in full.

GSTM1 / GSTT1 — glutathione backup when COMT methylation is insufficient. When MTHFR-constrained SAMe limits COMT throughput, glutathione S-transferases provide a secondary clearance route for 4-OHE2-derived quinones. Null GSTM1/GSTT1 deletions eliminate that backup — making MTHFR impairment more consequential when glutathione capacity is also absent. GSTM1 and GSTT1: Glutathione and Hormone Detox covers this downstream layer.

SULT1A1 — parallel Phase 2 sulfation. SULT1A1 sulfates estrogens for excretion independently of methylation. Its activity doesn't depend on SAMe — making it a methylation-independent clearance route whose relative contribution increases when MTHFR-constrained methylation is operating below capacity. SULT1A1 Sulfation: Estrogen Detox Genetics covers the sulfation pathway.

ESR1 / ESR2 — receptor sensitivity to estrogens that slower clearance leaves in circulation longer. Estrogen receptor variants determine how sensitively tissues respond to the catechol estrogens and estradiol that persist when MTHFR-limited COMT clearance is slowed. Estrogen Receptor Genetics: ESR1 and ESR2 Variants covers receptor genetics in full.

What Your MTHFR Results Can and Cannot Tell You

MTHFR C677T and A1298C variant analysis reveals your genetic baseline for methylation cycle throughput — specifically the efficiency of the 5,10-methyleneTHF to 5-MTHF conversion step that feeds SAMe synthesis. Results do not measure your current homocysteine level, folate status, or SAMe concentration; those require laboratory testing. They do not diagnose any condition. And they do not predict your response to any specific estrogen-pathway compound or hormone protocol.

What they deliver is the upstream metabolic context: whether your methylation cycle is genetically predisposed to run at full capacity or at a partial throughput that constrains every SAMe-dependent reaction downstream — including the COMT-mediated estrogen clearance that is central to women's hormonal health. Genetics as a guide, not a guarantee — and as one of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights, MTHFR status gives providers the upstream picture that blood estrogen levels and COMT genetics alone cannot complete.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your MTHFR genotype and how your methylation capacity connects to your complete hormone profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About MTHFR and Women's Hormones

How does MTHFR affect women's hormone balance?

MTHFR variants reduce 5-MTHF production, limiting SAMe synthesis. Lower SAMe constrains COMT — the enzyme that methylates catechol estrogens in Phase 2 clearance. Slower COMT extends catechol estrogen activity even when estradiol production is normal. The Precision Peptide Genetic Test analyzes MTHFR alongside COMT as part of 6 Reproductive Health insights within 14 pathways.

What is the difference between MTHFR C677T and A1298C?

C677T (rs1801133) affects enzyme thermostability and is the more functionally impactful single variant — reducing activity approximately 35% heterozygous and 60–70% homozygous. A1298C (rs1801131) affects allosteric regulation and reduces activity approximately 40% heterozygous. Compound heterozygous C677T/A1298C produces combined impairment comparable to T/T in some contexts. The Precision Peptide Genetic Test identifies both variants together.

Why does MTHFR genotype matter for women considering estrogen-pathway support?

Any estrogen-pathway support increases the catechol estrogen load COMT must clear — and COMT depends on SAMe that MTHFR helps produce. Impaired MTHFR constrains that SAMe supply before additional estrogen substrate arrives. Knowing MTHFR status in advance allows providers to establish methylation support proactively, within 14 pathways and 150+ genetic insights.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.